Stockscreener 앱 받기
14.06
5.00%
-0.74
Bicara Therapeutics Inc 주식(BCAX)의 최신 뉴스
FMR LLC's Strategic Acquisition of Bicara Therapeutics Inc Shares - GuruFocus
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Published on: 2026-02-04 16:21:43 - baoquankhu1.vn
Aug Technicals: Why is Bicara Therapeutics Inc stock going downTrade Risk Assessment & Fast Entry Momentum Alerts - baoquankhu1.vn
Aug Breakouts: Why is Bicara Therapeutics Inc stock going downWeekly Investment Report & Consistent Growth Stock Picks - baoquankhu1.vn
Bicara Therapeutics Inc. (NASDAQ:BCAX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Citizens Initiates Coverage of Bicara Therapeutics (BCAX) with Market Outperform Recommendation - Nasdaq
Bicara Therapeutics (NASDAQ:BCAX) Now Covered by Citizens Jmp - MarketBeat
Citizens initiates coverage on Bicara Therapeutics stock with Market Outperform rating By Investing.com - Investing.com Nigeria
Citizens initiates coverage on Bicara Therapeutics stock with Market Outperform rating - Investing.com Canada
Ivan Hyep Sells 1,882 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock - Defense World
Hyep Ivan, CFO of Bicara Therapeutics, sells $34,162 in BCAX stock - Investing.com Canada
Ryan Cohlhepp Sells 3,828 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock - MarketBeat
Stocks showing improving market leadership: Bicara Therapeutics earns 82 RS rating - MSN
Bicara Therapeutics (BCAX) Investor Outlook: A 74.97% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Analyst Upgrade: Should I set a stop loss on Bicara Therapeutics IncOptions Play & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Stocks To Watch: Bicara Therapeutics Sees Relative Strength Rating Rise To 81 - Investor's Business Daily
Quarterly Earnings: What are analysts price targets for Bicara Therapeutics IncVolume Spike & Real-Time Buy Signal Alerts - baoquankhu1.vn
BCAX: De-Risked FORTIFI-HN01 Path, Differentiated Ficera Profile, and Solid Cash Runway Underpin Buy Rating and $28 Target - TipRanks
Bicara Therapeutics Inc. (BCAX) Investor Outlook: Exploring an 84% Potential Upside in Biotechnology - DirectorsTalk Interviews
Bicara Therapeutics stock maintains Buy rating at BTIG on clinical progress - Investing.com Nigeria
Analysts Have Conflicting Sentiments on These Healthcare Companies: Bicara Therapeutics Inc. (BCAX), NewAmsterdam Pharma Company (NAMS) and GE Healthcare Technologies Inc (GEHC) - The Globe and Mail
Does Bicara Therapeutics Inc align with a passive investing strategyDividend Hike & Weekly Market Pulse Updates - baoquankhu1.vn
H.C. Wainwright reiterates Buy rating on Bicara Therapeutics stock By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Buy rating on Bicara Therapeutics stock - Investing.com
How cyclical is Bicara Therapeutics Inc.’s revenue stream2025 Market Outlook & Daily Growth Stock Investment Tips - Bollywood Helpline
Bicara Therapeutics (NASDAQ:BCAX) Given Outperform Rating at Wedbush - Defense World
Growth Report: Will Bicara Therapeutics Inc. stock continue upward momentumJuly 2025 Opening Moves & Weekly Breakout Watchlists - Bộ Nội Vụ
Wedbush Reaffirms Outperform Rating for Bicara Therapeutics (NASDAQ:BCAX) - MarketBeat
Bicara selects optimal dose for head and neck cancer drug in pivotal study - Investing.com Nigeria
Bicara Therapeutics Touts Breakthrough Ficerafusp Data, Picks 1,500 mg Dose for FORTIFY-HNS Trial - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Shares Down 7%Time to Sell? - MarketBeat
BCAX: Ficerafusp alfa shows deep, durable responses and blockbuster potential in head and neck cancer - TradingView
Bicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook - Sahm
Bicara Sets Phase 3 Path for Ficerafusp Alfa - TipRanks
Bicara Therapeutics announces phase 3 optimal dose and provides 2026 corporate outlook - marketscreener.com
Bicara Therapeutics Inc Announces Phase 3 Optimal Dose and 2026 Outlook - TradingView
Bicara Therapeutics Announces Phase 3 Optimal Dose And Provides 2026 Corporate Outlook - TradingView
Published on: 2026-01-12 06:24:33 - moha.gov.vn
Bicara Therapeutics (NASDAQ:BCAX) Trading 7.8% Higher – Should You Buy? - Defense World
Is Bicara Therapeutics Inc. stock trading at a premium valuationWeekly Trade Review & Precise Trade Entry Recommendations - ulpravda.ru
BTIG Research Begins Coverage on Bicara Therapeutics (NASDAQ:BCAX) - Defense World
Bicara Therapeutics Inc.Common Stock (NQ: BCAX - FinancialContent
Bicara Therapeutics (NASDAQ:BCAX) Trading Up 7.8%Here's Why - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Upgraded to "Strong-Buy" at BTIG Research - MarketBeat
Published on: 2026-01-09 02:43:58 - Улправда
Is Bicara Therapeutics Inc. stock a defensive play in 2025July 2025 Breakouts & Safe Entry Trade Signal Reports - Улправда
1.24%
0.19%
자본화:
|
볼륨(24시간):